W

ell, this is stunning: Looks like Grail, the Illumina spinout that’s working on an early blood-based screening test for cancer, will be raising a Series B round that clocks in at more than $1 billion.

The company just put out a statement that a number of undisclosed investors are seriously interested in doling out this cash. Fast Company last month had reported that the company was looking to raise $1.7 billion.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Link exchange is nothing else but it is just placing the other person’s website link on your page at appropriate place and other person will also do same in support of you.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.